|Videos|August 3, 2015

Will Biosimilars Impact the Cost of Specialty Drugs?

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME